Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Friedrichshall – page 29

851 clinical trials in Bad Friedrichshall, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Friedrichshall at a glance
851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

851 trials in Bad Friedrichshall

Open in trial search

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Psoriasis

Not yet recruiting

Long-term Safety and Efficacy of ORKA-001 in Adults with Moderate-to-Severe Plaque Psoriasis (Open-Label Extension Study)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORKA-001
  • Sponsor:Oruka Therapeutics Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-88545223
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Carcinoid syndrome

Not yet recruiting

Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Friedrichshall

What the registry says about research in the country

01 Cardiovascular Disease Research

Clinical trials focusing on atherosclerotic cardiovascular disease are evaluating innovative therapies to reduce major adverse cardiovascular events. These studies aim to improve outcomes for patients at high cardiovascular risk.

  • Coronary Heart Disease
  • Myocardial Infarction
  • Ischemic Stroke Prevention

Research emphasizes the development of new therapeutic approaches for arterial health management.

02 Heart Failure Studies

Groundbreaking research combines empagliflozin with novel compounds to address heart failure management. These trials specifically target patients with reduced left ventricular ejection fraction.

  • Combination Therapy Assessment
  • Cardiovascular Mortality Reduction
  • Hospital Admission Prevention

The studies aim to enhance current treatment protocols for heart failure patients.

03 Cardiac Rhythm Management

Important clinical research in atrial fibrillation and acute coronary syndrome is evaluating new anticoagulation strategies. These trials focus on preventing cardioembolic events and improving post-heart attack outcomes.

  • Stroke Prevention
  • Systemic Embolism Prevention
  • Post-Heart Attack Care

The research aims to establish more effective therapeutic options for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.